RxDoctor Payments Data

Thomas Quinn, DO

Rheumatology · Blue Bell, PANPI 1568818615

Payments from drug & device makers

$25,656in general payments, 2019–2025

Across 456 payments — averaging $56.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$18K
  • AbbVie$1K
  • AstraZeneca$1K
  • Johnson & Johnson$796
  • UCB, Inc.$771
  • ANI Pharmaceuticals, Inc.$556
  • plus $3K from 19 others

What the payments were for

  • Speaking & faculty fees$14,82058%
  • Food & beverage$10,73342%
  • Education$1020%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,656 in reported general payments places this provider in the 75th percentile of 351 rheumatology providers in Pennsylvania.

See all rheumatology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$230,249
Medicare patients
629
Services billed
5,080

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban327$157,160
Cosentyx Sensoready (2 Pens)Secukinumab12$91,234
OtezlaApremilast17$83,136
Xeljanz XrTofacitinib Citrate14$80,263
GemtesaVibegron133$56,409
JardianceEmpagliflozin50$26,577
XareltoRivaroxaban39$16,482
MultaqDronedarone Hcl21$15,084
TradjentaLinagliptin28$12,082
MyrbetriqMirabegron19$8,349
BrilintaTicagrelor19$8,335
Hydroxychloroquine Sulfate176$6,832
Pantoprazole Sodium291$5,116
Potassium Chloride283$5,012
Metoprolol Succinate301$4,509

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$463$157,160327 claims
AmgenOtezla$18,301$83,13617 claims
Boehringer IngelheimJardiance, Tradjenta$90$38,65978 claims
Johnson & JohnsonXarelto$796$16,48239 claims
AstraZenecaBrilinta$1,121$8,33519 claims
Almatica Pharma LLCSertraline Hcl$24$1,846142 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 351 rheumatology providers in Pennsylvania.

Other rheumatology in Blue Bell

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →